Invention:
This technology is a new method to develop patient-specific CAR T-cells for conditions characterized by uncontrolled proliferation of T-cells, such as T-cell lymphoma. This approach directs CAR-T cells only to T cells of a given clonal type. There are millions of T cell clones in each patient, each bearing a unique T cell receptor. Here, the inherent specificity of T cells is used to target only malignant T cells clones, resulting in little or no off-target binding and virtually no on-target off-tumor binding. Since typically all the malignant cells in an individual patient with T cell leukemia/lymphoma derive from just one clone, a CAR-T approach directed against this one clone has exquisite specificity, in principle much more specificity than any other CAR-T approach now available or in the pipeline.
Background:
Chimeric antigen receptor (CAR) T-cell therapy provides a promising way of treating cancer, especially in patients with blood-related cancers. It has been a challenge in the T cell setting to identify an appropriate cell-surface target like the CD19-B cell target. More importantly, ablation of a patient's T cell population via CAR-T therapy may not be manageable the way that B cell ablation is (via use of immunoglobulins). And, for any CAR-T approach, off target binding and on-target off-tumor binding that contributes to cytokine release syndrome is a big concern. This new technology aims to decrease off-target side effects by creating a more specified CAR t-cell that is completely patient specific.
Applications:
- Cancer immunotherapy
- T-cell proliferation disorders
Advantages:
- Patient specific
- Provides a more targeted and effective approach
- Potential to reduce side effects of current CAR T-cell therapy
